Home
    • Plans Blog Contact
    DR REDDYS LABORATORIES LTD logo

    DR REDDYS LABORATORIES LTD

    RDY
    Last price US$12.28
    Market cap US$10.4b
    12M price change -12.97%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    DR REDDYS LABORATORIES LTD Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment m Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for DR REDDYS LABORATORIES LTD into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 03, 2026

    Quarterly result summary

    Exhibit 99.1 Dr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: [email protected] Web: www.drreddys.com August 1, 2026 Nationa...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 6-K Aug 13, 2026 SEC filing RDY0934_6K Aug 10, 2026 SEC filing FORM 6-K Aug 03, 2026 SEC filing FORM 6-K Jul 29, 2026 Transcript exhibit EXHIBIT 99.1 Jul 29, 2026 SEC filing FORM 6-K Jul 29, 2026 SEC filing FORM 6-K Jul 23, 2026 SEC filing FORM 6-K Jul 23, 2026 SEC filing FORM 6-K Jul 23, 2026 SEC filing FORM 6-K Jul 23, 2026 Earnings release EXHIBIT 99.1 Jul 23, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    DR REDDYS LABORATORIES LTD boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 1.96/5
    DR REDDYS LABORATORIES LTD exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    DR REDDYS LA... RDY US$10.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    DR REDDYS LABORATORIES LTD olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    DR REDDYS LA... RDY US$10.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 2.58/5
    DR REDDYS LABORATORIES LTD attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    DR REDDYS LA... RDY US$10.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    DR REDDYS LABORATORIES LTD logo

    DR REDDYS LABORATORIES LTD

    US$12.28

    US$10.4b

    0.49%

    -12.97%